Former President Joe Biden recently underwent Mohs surgery for skin cancer, adding to his history of skin cancer treatments, and was seen with a bandage on his head, indicating ongoing dermatologic care.
Moderna's stock surged by over 9% after positive trial results for a skin cancer treatment developed in collaboration with Merck. The treatment combines a vaccine with Merck's Keytruda drug and has shown promising results in reducing the risk of melanoma recurrence by up to 49% after three years. Meanwhile, Pfizer's stock dropped more than 2% due to a disappointing 2024 outlook, with the company downgrading its forecast to be flat compared to 2023 and estimating lower revenue from its COVID portfolio. Analysts have expressed doubts about Pfizer's growth prospects and its ability to recover from patent expiries in the future.